⌘K (Command K) to search

Sign in Sign up free

Insider · CIK 0001857822

Asanuma Sakae

Reports to the SEC for 1 company · CAMBRIDGE, MA

Transactions

6

Companies

1

Filings

1

CIK

0001857822

Forms 4 and 5

Insider transactions

6 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2021-05-04	HOWLWerewolf Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+1.32M sh	—	—	1,318,311
2021-05-04	HOWLWerewolf Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+438K sh	—	—	1,756,409
2021-05-04	HOWLWerewolf Therapeutics, Inc.P Purchase	Director, 10% Owner	PPurchase	+313K sh	$16.00	+$5M	2,068,909
2021-05-04	HOWLWerewolf Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−11.4M sh	—	—	0
2021-05-04	HOWLWerewolf Therapeutics, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−3.8M sh	—	—	0
2020-12-23	HOWLWerewolf Therapeutics, Inc. · Series B Preferred StockP Purchase	Director, 10% Owner	PPurchase	+3.8M sh	$0.92	+$3.5M	3,797,921

Recent filings

1

Accepted (ET)
May 44
Asanuma Sakae0000899243-21-018116
SEC(opens sec.gov)

Companies

1

Werewolf Therapeutics, Inc.Director, 10% OwnerHOWL

Address

C/O WEREWOLF THERAPEUTICS, INC. 1030 MASSACHUSETTS AVENUE, SUITE 210

CAMBRIDGE, MA, 02138